- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. - Today announced Positive Opinion from the European Medicines Agency on Orphan Drug Designation for KB407 for the treatment of cystic fibrosis.

PITTSBURGH , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer will be participating in a fireside chat at the 41 st Annual

PITTSBURGH , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public

PITTSBURGH --(BUSINESS WIRE)--Feb. 2, 2021-- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock.

PITTSBURGH --(BUSINESS WIRE)--Jan. 4, 2021-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason , MD, PhD, FRCS, FMedSci, and Jing L. Marantz , MD, PhD, MBA to its board of directors.

PITTSBURGH --(BUSINESS WIRE)--Nov. 24, 2020-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan , chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd

- Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars - Today announced additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis - Strong balance sheet with cash,

PITTSBURGH --(BUSINESS WIRE)--Oct. 16, 2020-- Krystal Biotech , Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal’s commercial team will report directly to Chief Executive

- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling PITTSBURGH --(BUSINESS WIRE)--Oct. 8, 2020-- Krystal Biotech , Inc.

PITTSBURGH --(BUSINESS WIRE)--Sep. 24, 2020-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S.